Insights

Why Intellia Therapeutics Stock Is Sinking Today

What happened

Shares of Intellia Therapeutics (NASDAQ: NTLA) are sinking today, down by 13.3% as of 11:01 a.m. ET. The decline came after the biotech company provided its second-quarter update earlier in the morning.

Intellia reported Q2 collaboration revenue of $14 million, up from $6.6 million in the prior-year period. The company posted a net loss of $100.7 million, or $1.33 per diluted share. This result was slightly worse than the consensus estimate for net loss of $1.31 per share.

In addition to announcing its financial results, Intellia revealed that it plans to focus exclusively on developing ex vivo (out of the body) allogeneic (commonly referred to as off-the-shelf) cell therapies. As part of this move, the company said that it’s discontinuing a clinical study evaluating experimental cell therapy NTLA-5001, which uses genetically engineered cells from patients. Intellia stated that it plans to pivot to an off-the-shelf version of the therapy that’s currently in preclinical development.

So what

Today’s decline threatens to stop a solid comeback for Intellia. The genomics stock had fallen as much as 67% year to date but was up 33% over the past month prior to the Q2 update.

Investors appear to be more concerned about Intellia’s decision to throw in the towel on developing ex vivo autologous therapies than they are about the small earnings miss. NTLA-5001 was one of only four clinical-stage programs for the company. 

Intellia insisted that its decision wasn’t based on negative safety or efficacy findings in the clinical trial evaluating NTLA-5001. Instead, the company said the focus on off-the-shelf cell therapy development was based on the potential to “consistently deliver a high-quality, readily available and persistent cell product for treatment of aggressive cancers.”  

Now what

Importantly, Intellia’s change of direction doesn’t impact its in vivo (inside the body) programs. The company expects to report key interim clinical results for NTLA-2001 in treating transthyretin amyloidosis and for NTLA-2002 in treating hereditary angioedema later this year.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Intellia Therapeutics. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Rebate Rewards

Level 2 Rebate

Deposit $2,000 and get $200 Rebate
$ 200 Rebate
  • 3 Simple Steps
  • 1. Register Using The Link Below (Promo-Code: WEBREBATE)
  • 2. Deposit $2,000 and place one trade at any non-Austalian market within 30 calendar days
  • 3. Receive Your $200 Rebate
Popular

Level 1 Rebate

Deposit $1,000 and get $100 Rebate
$ 100 Rebate
  • 3 Simple Steps
  • 1. Register Using The Link Below (Promo-Code: WEBREBATE)
  • 2. Deposit $1,000 and place one trade at any non-Austalian market within 30 calendar days
  • 3. Receive Your $100 Rebate

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex Securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

EASY QUALIFICATION & LOW ENTRY
NEW CLIENT REBATE OFFER
EARN UP TO $200 CASH REBATE
Act Fast - Promotion Ends In
Click Here To Get Started
EASY QUALIFICATION & LOW ENTRY
NEW CLIENT REBATE OFFER
EARN UP TO $200 CASH REBATE
Act Fast - Promotion Ends In
Click Here For More Info